Alphatec (NASDAQ:ATEC) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Alphatec (NASDAQ:ATEC) announced its earnings results on Wednesday. The medical technology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.04), Zacks reports. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%.

Alphatec Trading Up 4.7 %

Shares of NASDAQ:ATEC traded up $0.50 during mid-day trading on Wednesday, hitting $11.06. The company had a trading volume of 2,444,738 shares, compared to its average volume of 1,616,703. The company has a market capitalization of $1.57 billion, a PE ratio of -8.64 and a beta of 1.43. The firm has a fifty day moving average price of $10.52 and a 200 day moving average price of $8.33. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec has a one year low of $4.88 and a one year high of $15.41.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. Needham & Company LLC lifted their target price on shares of Alphatec from $13.00 to $16.00 and gave the company a “buy” rating in a research note on Monday, January 13th. Barclays raised their price target on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Alphatec in a research report on Tuesday, January 14th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Alphatec currently has a consensus rating of “Moderate Buy” and an average price target of $17.56.

Insider Buying and Selling at Alphatec

In related news, EVP David Sponsel sold 58,283 shares of the company’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $10.71, for a total transaction of $624,210.93. Following the sale, the executive vice president now owns 502,311 shares of the company’s stock, valued at approximately $5,379,750.81. This represents a 10.40 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Patrick Miles sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $12.03, for a total value of $601,500.00. Following the completion of the sale, the chief executive officer now owns 6,152,544 shares of the company’s stock, valued at $74,015,104.32. The trade was a 0.81 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 222,376 shares of company stock valued at $2,557,148. Corporate insiders own 22.80% of the company’s stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.